Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical ResearchStrattmont Group
Rockville, MD, April 2, 2017 – Precision-Biologics Inc. today announced an abstract reporting data on the company’s neo-antigen program has been accepted for an oral presentation at the upcoming 110th Annual Meeting of the American Association of Clinical Research (AACR) in Washington D.C., April 1-5, 2017.
“Precision Biologics continues to make progress with our preclinical and clinical programs,” said Philip M. Arlen, President and CEO of Precision Biologics. “As this study demonstrates, our novel, humanized IgG1 monoclonal antibody, NEO-201, specifically targets a neoantigen expressed on a broad range of solid tumors. Tumor cell killing, antibody-dependent, cell-mediated cytotoxicity (ADCC), was significantly enhanced when NEO-201 was combined with an allogenic source of natural killer cells.”
Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies
- Abstract #3025,http://www.abstractsonline.com/pp8/#!/4292/presentation/5981
- Presenter: Kristen Zeligs, MD Walter Reed National Military Medical Center, Bethesda, MD
- Monday, April 3, 2017, 4:05-4:20PM, Ballroom A-B
This oral presentation will present preclinical data demonstrating the potential benefit of targeting the NEO-201 neoantigen in both cancer cell lines as well as patient’s tumors. NEO-201 monoclonal antibody was shown to mediate ADCC activity, which was further enhanced when used with allogenic natural killer cells in tumor cell lines expressing the NEO-201 neoantigen. The NEO-201 antigen is expressed on numerous solid tumors with minimal expression on healthy tissue. The company plans to move this program into human clinical trials in the near future.
About Precision Biologics
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer. For more information on Precision Biologics, please visit http://www.precision-biologics.com/.